Treatment with a specific ACK1 inhibitor AIM-100 or ACK1 siRNA markedly inhibits cell migration in imatinib sensitive and in imatinib resistant GIST cell lines, which is associated with inactivation of PI3K/AKT/mTOR and RAF/MAPK signaling pathways [167]. Here, AKT1 is linked to gastrointestinal stromal tumor.